| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 0 | 0 | 19.543 | 15.418 | 11.378 | 2.928 | 28.691 | 89.100 | 62.179 |
| Total Income - EUR | - | 0 | 55 | 19.722 | 15.886 | 11.851 | 3.696 | 28.728 | 89.518 | 64.514 |
| Total Expenses - EUR | - | 1.643 | 1.867 | 6.047 | 12.212 | 8.581 | 11.296 | 11.555 | 20.071 | 30.855 |
| Gross Profit/Loss - EUR | - | -1.643 | -1.812 | 13.675 | 3.674 | 3.271 | -7.600 | 17.173 | 69.448 | 33.659 |
| Net Profit/Loss - EUR | - | -1.643 | -1.813 | 13.480 | 3.517 | 3.160 | -7.635 | 16.892 | 68.572 | 32.128 |
| Employees | - | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
Check the financial reports for the company - Arobiopharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 738 | 2.842 | 3.781 | 1.499 | 476 | 26.291 |
| Current Assets | - | 1.647 | 2.093 | 15.751 | 18.974 | 19.855 | 5.753 | 28.106 | 106.732 | 82.240 |
| Inventories | - | 126 | 418 | 121 | 434 | 426 | 585 | 586 | 3.407 | 837 |
| Receivables | - | 1.498 | 1.579 | 1.789 | 1.994 | 6.143 | 2.376 | 18.556 | 20.125 | 4.175 |
| Cash | - | 23 | 96 | 13.840 | 16.546 | 13.286 | 2.792 | 8.964 | 83.199 | 77.228 |
| Shareholders Funds | - | -7.359 | -9.048 | 4.598 | 8.026 | 11.034 | -2.165 | 14.720 | 67.833 | 91.061 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 9.006 | 11.141 | 11.153 | 11.703 | 11.662 | 11.700 | 14.886 | 39.376 | 17.470 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "1089 - 1089" | |||||||||
| CAEN Financial Year |
6201
|
|||||||||
Comments - Arobiopharm Srl